



FIRST RESOURCES LIMITED

Unaudited Financial Statements for the Fourth Quarter (“4Q”) and Full Year Ended 31 December 2014

PART I - INFORMATION REQUIRED FOR ANNOUNCEMENTS OF QUARTERLY (Q1, Q2 & Q3), HALF-YEAR AND FULL YEAR RESULTS

1(a) An income statement and statement of comprehensive income or a statement of comprehensive income for the group together with a comparative statement for the corresponding period of the immediately preceding financial year

	Group					
	FY 2014	FY 2013	Change	4Q 2014	4Q 2013	Change
	US\$'000	US\$'000	(%)	US\$'000	US\$'000	(%)
Sales	615,524	626,498	(1.8%)	176,672	179,129	(1.4%)
Cost of sales	(292,125)	(244,755)	19.4%	(74,679)	(70,909)	5.3%
Gross profit	323,399	381,743	(15.3%)	101,993	108,220	(5.8%)
Gains arising from changes in fair value of biological assets	1,940	29,564	(93.4%)	1,940	29,564	(93.4%)
Selling and distribution costs	(24,310)	(37,246)	(34.7%)	(6,079)	(9,029)	(32.7%)
General and administrative expenses	(28,339)	(31,638)	(10.4%)	(8,546)	(9,473)	(9.8%)
Other operating expenses	(1,697)	(1,589)	6.8%	(420)	(359)	17.0%
Profit from operations	270,993	340,834	(20.5%)	88,888	118,923	(25.3%)
(Losses)/gains on foreign exchange	(118)	(6,368)	(98.1%)	1,001	1,052	(4.8%)
(Losses)/gains on derivative financial instruments	(2,777)	(2,602)	6.7%	189	2,901	(93.5%)
Net financial expenses	(15,020)	(18,332)	(18.1%)	(4,249)	(3,291)	29.1%
Other non-operating (expenses)/income	(1,133)	32	n.m.	(579)	1,074	n.m.
Profit before tax	251,945	313,564	(19.7%)	85,250	120,659	(29.3%)
Tax expense	(71,154)	(67,454)	5.5%	(24,067)	(31,886)	(24.5%)
Profit for the year/period	180,791	246,110	(26.5%)	61,183	88,773	(31.1%)
Profit attributable to:						
Owners of the Company	173,409	238,242	(27.2%)	59,184	85,544	(30.8%)
Non-controlling interests	7,382	7,868	(6.2%)	1,999	3,229	(38.1%)
	180,791	246,110	(26.5%)	61,183	88,773	(31.1%)

n.m. – not meaningful

1(a) An income statement and statement of comprehensive income (continued)

	Group					
	FY 2014	FY 2013	Change	4Q 2014	4Q 2013	Change
	US\$'000	US\$'000	(%)	US\$'000	US\$'000	(%)
Profit for the year/period	180,791	246,110	(26.5%)	61,183	88,773	(31.1%)
Other comprehensive income:						
Items that will not be reclassified subsequently to profit or loss						
Remeasurement gains on defined benefits plan	1,125	2,245	(49.9%)	1,125	2,245	(49.9%)
Income tax effect	(235)	(561)	(58.1%)	(235)	(561)	(58.1%)
	890	1,684	(47.1%)	890	1,684	(47.1%)
Items that may be reclassified subsequently to profit or loss						
Fair value losses on cash flow hedges	(39,788)	(38,291)	3.9%	(48,546)	(9,560)	407.8%
Fair value losses on cash flow hedges transferred to the income statement	34,710	11,144	211.5%	38,807	(967)	n.m.
Foreign currency translation	(44,909)	(304,317)	(85.2%)	(26,979)	(67,203)	(59.9%)
Income tax effect	1,300	16,644	(92.2%)	1,180	3,739	(68.4%)
	(48,687)	(314,820)	(84.5%)	(35,538)	(73,991)	(52.0%)
Other comprehensive income for the year/period, net of tax	(47,797)	(313,136)	(84.7%)	(34,648)	(72,307)	(52.1%)
Total comprehensive income for the year/period	132,994	(67,026)	n.m.	26,535	16,466	61.2%
Total comprehensive income attributable to:						
Owners of the Company	126,808	(61,911)	n.m.	25,421	15,794	61.0%
Non-controlling interests	6,186	(5,115)	n.m.	1,114	672	65.8%
	132,994	(67,026)	n.m.	26,535	16,466	61.2%

n.m. – not meaningful

1(a) An income statement and statement of comprehensive income (continued)

Additional Information

	Group					
	FY 2014	FY 2013	Change	4Q 2014	4Q 2013	Change
	US\$'000	US\$'000	(%)	US\$'000	US\$'000	(%)
EBITDA						
Profit from operations	270,993	340,834	(20.5%)	88,888	118,923	(25.3%)
Depreciation and amortisation	30,695	27,646	11.0%	7,690	6,986	10.1%
Gains arising from changes in fair value of biological assets	(1,940)	(29,564)	(93.4%)	(1,940)	(29,564)	(93.4%)
EBITDA	299,748	338,916	(11.6%)	94,638	96,345	(1.8%)
EBITDA margin	48.7%	54.1%		53.6%	53.8%	

	Group					
	FY 2014	FY 2013	Change	4Q 2014	4Q 2013	Change
	US\$'000	US\$'000	(%)	US\$'000	US\$'000	(%)
Underlying Net Profit						
Profit for the year/period	180,791	246,110	(26.5%)	61,183	88,773	(31.1%)
Gains arising from changes in fair value of biological assets	(1,940)	(29,564)	(93.4%)	(1,940)	(29,564)	(93.4%)
Tax on gains arising from changes in fair value of biological assets	485	7,391	(93.4%)	485	7,391	(93.4%)
Underlying net profit for the year/period	179,336	223,937	(19.9%)	59,728	66,600	(10.3%)
Underlying net profit attributable to:						
Owners of the Company	171,640	216,958	(20.9%)	57,415	64,260	(10.7%)
Non-controlling interests	7,696	6,979	10.3%	2,313	2,340	(1.2%)
	179,336	223,937	(19.9%)	59,728	66,600	(10.3%)

1(b)(i) A statement of financial position (for the issuer and group), together with a comparative statement as at the end of the immediately preceding financial year

	Group		Company	
	31 Dec 2014	31 Dec 2013	31 Dec 2014	31 Dec 2013
	US\$'000	US\$'000	US\$'000	US\$'000
ASSETS				
Non-current assets				
Biological assets	961,083	869,309	-	-
Plasma plantation receivables	59,206	27,757	-	-
Property, plant and equipment	338,415	303,083	9,296	9,972
Land use rights	46,139	43,464	-	-
Investment in subsidiaries	-	-	452,291	452,291
Goodwill	60,994	73,277	-	-
Other intangible assets	24,932	29,067	323	451
Tax recoverable	13,431	7,741	-	-
Deferred tax assets	16,652	14,220	-	-
Loans to subsidiaries	-	-	440,881	438,729
Other non-current assets	2,094	2,110	-	-
Total non-current assets	1,522,946	1,370,028	902,791	901,443
Current assets				
Inventories	48,563	59,211	-	-
Loan to subsidiary	-	-	934	600
Trade receivables	29,769	34,922	1,743	2,499
Other receivables	9,312	6,998	7,401	987
Derivative financial assets	-	3,987	-	-
Advances for purchase of plant, property and equipment	4,235	5,666	-	23
Other advances and prepayments	2,188	3,280	60	103
Prepaid taxes	29,926	24,030	-	-
Restricted cash balances	59,460	32,675	58,438	27,999
Cash and cash equivalents	291,456	239,477	86,013	8,684
Total current assets	474,909	410,246	154,589	40,895
Total assets	1,997,855	1,780,274	1,057,380	942,338

1(b)(i) A statement of financial position (continued)

	Group		Company	
	31 Dec 2014	31 Dec 2013	31 Dec 2014	31 Dec 2013
	US\$'000	US\$'000	US\$'000	US\$'000
LIABILITIES				
Current liabilities				
Trade payables	20,075	24,498	188	1
Other payables and accruals	36,884	35,462	10,228	10,159
Advances from customers	2,071	1,360	-	-
Loans and borrowings from financial institutions	10,946	2,608	-	7
Derivative financial liabilities	-	1,210	-	-
Provision for tax	18,315	15,312	43	-
Total current liabilities	88,291	80,450	10,459	10,167
Non-current liabilities				
Loans and borrowings from financial institutions	2,740	2,733	-	-
Islamic medium term notes	569,433	484,388	569,433	484,388
Derivative financial liabilities	91,198	48,061	91,198	48,061
Provision for post-employment benefits	13,413	11,623	-	-
Deferred tax liabilities	117,030	112,894	985	402
Total non-current liabilities	793,814	659,699	661,616	532,851
Total liabilities	882,105	740,149	672,075	543,018
Net assets	1,115,750	1,040,125	385,305	399,320
EQUITY				
Share capital	394,913	394,913	394,913	394,913
Differences arising from restructuring transactions involving entities under common control	35,016	35,016	-	-
Other reserves	(396,366)	(348,922)	(12,723)	(7,645)
Retained earnings	1,029,626	912,472	3,115	12,052
Equity attributable to owners of the Company	1,063,189	993,479	385,305	399,320
Non-controlling interests	52,561	46,646	-	-
Total equity	1,115,750	1,040,125	385,305	399,320

1(b)(ii) Aggregate amount of group's borrowings and debt securities

- amount repayable in one year or less, or on demand
- amount repayable after one year

	Group					
	As at 31 Dec 2014			As at 31 Dec 2013		
	Secured	Unsecured	Total	Secured	Unsecured	Total
	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000
Amount repayable in one year or less, or on demand	10,946	-	10,946	2,608	-	2,608
Amount repayable after one year	2,740	569,433	572,173	2,733	484,388	487,121
Total	13,686	569,433	583,119	5,341	484,388	489,729

Details of any collateral

The secured borrowings are collateralised by certain of the Group's biological assets, land use rights, property, plant and equipment.

1(c) A statement of cash flows (for the group), together with a comparative statement for the corresponding period of the immediately preceding financial year

	Group			
	FY 2014	FY 2013	4Q 2014	4Q 2013
	US\$'000	US\$'000	US\$'000	US\$'000
Cash flows from operating activities				
Profit before tax	251,945	313,564	85,250	120,659
Adjustments for:				
Depreciation of property, plant and equipment	28,612	25,851	7,160	6,581
Amortisation of land use rights and intangible assets	2,083	1,795	530	405
Gains on disposal of property, plant and equipment	(151)	-	(92)	-
Financial expenses	20,124	21,857	5,800	4,365
Interest income	(5,104)	(3,525)	(1,551)	(1,074)
Losses/(gains) on derivative financial instruments	2,777	2,602	(189)	(2,901)
Gains arising from changes in fair value of biological assets	(1,940)	(29,564)	(1,940)	(29,564)
Operating cash flows before changes in working capital	298,346	332,580	94,968	98,471
Changes in working capital:				
Inventories	9,695	(9,821)	21,982	11,353
Trade receivables	5,129	(12,864)	(869)	(17,943)
Other receivables	(2,022)	(15,452)	5,025	(524)
Advances and prepayments	1,076	13,968	633	2,187
Other non-current assets	(142)	165	(47)	30
Trade payables	(4,141)	6,646	(14,719)	(3,482)
Other payables and accruals	1,339	(4,777)	1,973	9,510
Advances from customers	773	(5,264)	(1,385)	(3,508)
Provision for post-employment benefits	3,308	3,734	2,222	1,181
Unrealised translation differences	69	(14,899)	2,068	(13,976)
Cash flows generated from operations	313,430	294,016	111,851	83,299
Financial expenses paid	(18,514)	(21,234)	(5,668)	(5,030)
Interest income received	4,668	3,417	922	969
Tax paid	(76,689)	(76,209)	(19,522)	(19,325)
Net cash generated from operating activities	222,895	199,990	87,583	59,913

1(c) Statement of cash flows (continued)

	Group			
	FY 2014	FY 2013	4Q 2014	4Q 2013
	US\$'000	US\$'000	US\$'000	US\$'000
Cash flows from investing activities				
Capital expenditure on biological assets	(132,778)	(116,678)	(45,103)	(43,123)
Capital expenditure on property, plant and equipment	(71,445)	(64,323)	(18,466)	(14,996)
Decrease/(increase) in advances for purchase of property, plant and equipment	1,377	1,242	1,584	(657)
Development costs on plasma plantations	(11,744)	(4,528)	(7,107)	(1,632)
Proceeds from plasma plantation receivables	1,919	19,685	1,362	19,565
Acquisition of land use rights	(1,924)	(823)	(40)	(376)
Acquisition of other intangible assets	(164)	(324)	-	(171)
Proceeds from disposal of property, plant and equipment	228	-	33	157
Net cash outflow on acquisition of subsidiaries	-	(69,756)	-	-
Net cash used in investing activities	(214,531)	(235,505)	(67,737)	(41,233)
Cash flows from financing activities				
Proceeds from bank loans	8,419	17,928	8,419	17,928
Repayment of bank loans	-	(250,688)	-	(4,798)
Proceeds from issuance of Islamic medium term notes, net	122,299	197,237	122,299	-
Payment of obligations under finance leases	(3,541)	(3,307)	(835)	(888)
Increase in restricted cash balances	(26,785)	(19,731)	(37,329)	(8,656)
Dividends paid	(57,633)	(51,002)	-	-
Proceeds from equity contribution by non-controlling interests	264	179	264	179
Net cash generated from/(used in) financing activities	43,023	(109,384)	92,818	3,765
Net increase/(decrease) in cash and cash equivalents	51,387	(144,899)	112,664	22,445
Effect of exchange rate changes on cash and cash equivalents	592	(7,418)	(1,840)	(1,412)
Cash and cash equivalents, at the beginning of the financial year/period	239,477	391,794	180,632	218,444
Cash and cash equivalents, at the end of the financial period (Note A)	291,456	239,477	291,456	239,477
<u>Note A</u>				
Reconciliation of cash and cash equivalents:				
Cash at banks and on hand	119,458	108,606	119,458	108,606
Time deposits	171,998	130,871	171,998	130,871
Cash and cash equivalents	291,456	239,477	291,456	239,477
Restricted cash balances	59,460	32,675	59,460	32,675
Cash and bank balances	350,916	272,152	350,916	272,152

1(d)(i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year

Group	----- Attributable to owners of the Company -----					Non-controlling interests	Total equity
	Share capital	Differences arising from restructuring transactions involving entities under common control	Other reserves	Retained earnings	Equity attributable to owners of the Company		
	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000		
At 1 Jan 2014	394,913	35,016	(348,922)	912,472	993,479	46,646	1,040,125
Profit for the year	-	-	-	173,409	173,409	7,382	180,791
<u>Other comprehensive income</u>							
Remeasurement gains on defined benefits plan	-	-	-	843	843	47	890
Net change in fair value of cash flow hedges	-	-	(5,078)	-	(5,078)	-	(5,078)
Foreign currency translation	-	-	(42,366)	-	(42,366)	(1,243)	(43,609)
Other comprehensive income for the year, net of tax	-	-	(47,444)	843	(46,601)	(1,196)	(47,797)
Total comprehensive income for the year	-	-	(47,444)	174,252	126,808	6,186	132,994
<u>Contributions by and distributions to owners</u>							
Dividends paid	-	-	-	(57,098)	(57,098)	(535)	(57,633)
<u>Changes in ownership interests in subsidiaries</u>							
Equity contribution by non-controlling interests	-	-	-	-	-	264	264
Total transactions with owners in their capacity as owners	-	-	-	(57,098)	(57,098)	(271)	(57,369)
At 31 Dec 2014	394,913	35,016	(396,366)	1,029,626	1,063,189	52,561	1,115,750
At 1 Jan 2013	394,913	35,016	(47,085)	723,548	1,106,392	51,180	1,157,572
Profit for the year	-	-	-	238,242	238,242	7,868	246,110
<u>Other comprehensive income</u>							
Remeasurement gains on defined benefits plan	-	-	-	1,684	1,684	-	1,684
Net change in fair value of cash flow hedges	-	-	(24,672)	-	(24,672)	215	(24,457)
Foreign currency translation	-	-	(277,165)	-	(277,165)	(13,198)	(290,363)
Other comprehensive income for the year, net of tax	-	-	(301,837)	1,684	(300,153)	(12,983)	(313,136)
Total comprehensive income for the year	-	-	(301,837)	239,926	(61,911)	(5,115)	(67,026)
<u>Contributions by and distributions to owners</u>							
Dividends paid	-	-	-	(51,002)	(51,002)	-	(51,002)
<u>Changes in ownership interests in subsidiaries</u>							
Equity contribution by non-controlling interests	-	-	-	-	-	179	179
Acquisition of subsidiaries	-	-	-	-	-	402	402
Total transactions with owners in their capacity as owners	-	-	-	(51,002)	(51,002)	581	(50,421)
At 31 Dec 2013	394,913	35,016	(348,922)	912,472	993,479	46,646	1,040,125

1(d)(i) Statement of changes in equity (continued)

Group	----- Attributable to owners of the Company -----					Non-controlling interests	Total equity
	Share capital	Differences arising from restructuring transactions involving entities under common control	Other reserves	Retained earnings	Equity attributable to owners of the Company		
	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000		
At 1 Oct 2014	394,913	35,016	(361,760)	969,599	1,037,768	51,183	1,088,951
Profit for the period	-	-	-	59,184	59,184	1,999	61,183
<u>Other comprehensive income</u>							
Remeasurement gains on defined benefits plan	-	-	-	843	843	47	890
Net change in fair value of cash flow hedges	-	-	(9,739)	-	(9,739)	-	(9,739)
Foreign currency translation	-	-	(24,867)	-	(24,867)	(932)	(25,799)
Other comprehensive income for the period, net of tax	-	-	(34,606)	843	(33,763)	(885)	(34,648)
Total comprehensive income for the period	-	-	(34,606)	60,027	25,421	1,114	26,535
<u>Changes in ownership interests in subsidiaries</u>							
Equity contribution by non-controlling interests	-	-	-	-	-	264	264
Total transactions with owners in their capacity as owners	-	-	-	-	-	264	264
At 31 Dec 2014	394,913	35,016	(396,366)	1,029,626	1,063,189	52,561	1,115,750
At 1 Oct 2013	394,913	35,016	(277,488)	825,244	977,685	45,393	1,023,078
Profit for the period	-	-	-	85,544	85,544	3,229	88,773
<u>Other comprehensive income</u>							
Remeasurement gains on defined benefits plan	-	-	-	1,684	1,684	-	1,684
Net change in fair value of cash flow hedges	-	-	(10,130)	-	(10,130)	380	(9,750)
Foreign currency translation	-	-	(61,304)	-	(61,304)	(2,937)	(64,241)
Other comprehensive income for the period, net of tax	-	-	(71,434)	1,684	(69,750)	(2,557)	(72,307)
Total comprehensive income for the period	-	-	(71,434)	87,228	15,794	672	16,466
<u>Changes in ownership interests in subsidiaries</u>							
Equity contribution by non-controlling interests	-	-	-	-	-	179	179
Acquisition of subsidiaries	-	-	-	-	-	402	402
Total transactions with owners in their capacity as owners	-	-	-	-	-	581	581
At 31 Dec 2013	394,913	35,016	(348,922)	912,472	993,479	46,646	1,040,125

1(d)(i) Statement of changes in equity (continued)

Company	Share capital	Other reserves	Retained earnings	Total equity
	US\$'000	US\$'000	US\$'000	US\$'000
At 1 Jan 2014	394,913	(7,645)	12,052	399,320
Profit for the year	-	-	48,161	48,161
<u>Other comprehensive income</u>				
Net change in fair value of cash flow hedges	-	(5,078)	-	(5,078)
Total comprehensive income for the year	-	(5,078)	48,161	43,083
<u>Contributions by and distributions to owners</u>				
Dividends paid	-	-	(57,098)	(57,098)
Total transactions with owners in their capacity as owners	-	-	(57,098)	(57,098)
At 31 Dec 2014	394,913	(12,723)	3,115	385,305
At 1 Jan 2013	394,913	2,150	5,248	402,311
Profit for the year	-	-	57,806	57,806
<u>Other comprehensive income</u>				
Net change in fair value of cash flow hedges	-	(9,795)	-	(9,795)
Total comprehensive income for the year	-	(9,795)	57,806	48,011
<u>Contributions by and distributions to owners</u>				
Dividends paid	-	-	(51,002)	(51,002)
Total transactions with owners in their capacity as owners	-	-	(51,002)	(51,002)
At 31 Dec 2013	394,913	(7,645)	12,052	399,320
At 1 Oct 2014	394,913	(2,984)	4,491	396,420
Profit for the period	-	-	(1,376)	(1,376)
<u>Other comprehensive income</u>				
Net change in fair value of cash flow hedges	-	(9,739)	-	(9,739)
Total comprehensive income for the period	-	(9,739)	(1,376)	(11,115)
At 31 Dec 2014	394,913	(12,723)	3,115	385,305
At 1 Oct 2013	394,913	(1,673)	6,150	399,390
Profit for the period	-	-	5,902	5,902
<u>Other comprehensive income</u>				
Net change in fair value of cash flow hedges	-	(5,972)	-	(5,972)
Total comprehensive income for the period	-	(5,972)	5,902	(70)
At 31 Dec 2013	394,913	(7,645)	12,052	399,320

1(d)(i) Statement of changes in equity (continued)**Other Reserves**

	Group		Company	
	As at		As at	
	31 Dec 2014	31 Dec 2013	31 Dec 2014	31 Dec 2013
	US\$'000	US\$'000	US\$'000	US\$'000
Capital reserve	(29,096)	(29,096)	-	-
Revaluation reserve	279	279	-	-
Gain on sale of treasury shares	10,322	10,322	10,322	10,322
Hedging reserve	(23,438)	(18,360)	(23,438)	(18,360)
Foreign translation reserve	(354,433)	(312,067)	393	393
Total other reserves	(396,366)	(348,922)	(12,723)	(7,645)

1(d)(ii) Details of any changes in the company's share capital arising from rights issue, bonus issue, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State also the number of shares that may be issued on conversion of all the outstanding convertibles, as well as the number of shares held as treasury shares, if any, against the total number of issued shares excluding treasury shares of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year

There were no changes to the Company's issued and paid up share capital in the three months ended 31 December 2014.

	Company	
	31 Dec 2014	31 Dec 2013
Number of issued shares excluding treasury shares	1,584,072,969	1,584,072,969

The Company did not hold any treasury shares and there were no shares that may be issued upon conversion of any outstanding convertibles as at 31 December 2014 and 31 December 2013.

1(d)(iii) To show the total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year

The Company's total number of issued shares excluding treasury shares as at 31 December 2014 and 31 December 2013 were 1,584,072,969.

1(d)(iv) A statement showing all sales, transfers, disposal, cancellation and/or use of treasury shares as at the end of the current financial period reported on

Not applicable.

2. Whether the figures have been audited, or reviewed and in accordance with which auditing standard or practice

The financial statements presented above have not been audited or reviewed by the Company's auditor.

3. Where the figures have been audited or reviewed, the auditors' report (including any qualifications or emphasis of matter)

Not applicable.

4. Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statements have been applied

The Group has applied the same accounting policies and methods of computation in the preparation of the financial statements as at 31 December 2013 except for the new and revised standards that are effective for annual periods beginning as of 1 January 2014. The adoption of these standards has no significant impact to the Group.

5. If there are any changes in the accounting policies and methods of computation, including any required by an accounting standard, what has changed, as well as the reasons for, and the effect of, the change

Please refer to item 4 above.

6. Earnings per ordinary share of the group for the current financial period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends

	Group			
	FY 2014	FY 2013	4Q 2014	4Q 2013
Weighted average number of shares applicable to basic EPS computation	1,584,072,969	1,584,072,969	1,584,072,969	1,584,072,969
Weighted average number of shares based on fully diluted basis	1,584,072,969	1,584,072,969	1,584,072,969	1,584,072,969
EPS - basic (US cents)	10.95	15.04	3.74	5.40
EPS - diluted (US cents)	10.95	15.04	3.74	5.40

7. Net asset value (for the issuer and group) per ordinary share based on the total number of issued shares excluding treasury shares of the issuer at the end of the:-

(a) current financial period reported on; and

(b) immediately preceding financial year

	Group		Company	
	31 Dec 2014	31 Dec 2013	31 Dec 2014	31 Dec 2013
	US\$	US\$	US\$	US\$
Net asset value per ordinary share	0.67	0.63	0.24	0.25

8. A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. It must include a discussion of the following:-
- (a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and
- (b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on

REVIEW OF GROUP FINANCIAL PERFORMANCE BY BUSINESS SEGMENT

SALES VOLUME

	FY 2014	FY 2013	Change	4Q 2014	4Q 2013	Change
	Tonne	Tonne	%	Tonne	Tonne	%
Plantations and Palm Oil Mills						
- Crude palm oil	658,803	625,202	5.4%	176,847	194,257	(9.0%)
- Palm kernel	142,594	136,966	4.1%	44,180	43,148	2.4%
Refinery and Processing	564,435	252,121	123.9%	154,327	110,541	39.6%

Note: Sales volume include inter-segment sales

SALES

	FY 2014	FY 2013	Change	4Q 2014	4Q 2013	Change
	US\$'000	US\$'000	%	US\$'000	US\$'000	%
Plantations and Palm Oil Mills						
- Crude palm oil	450,894	537,995	(16.2%)	114,058	153,673	(25.8%)
- Palm kernel	59,560	45,080	32.1%	15,203	14,916	1.9%
- Fresh fruit bunches	5,403	-	n.m.	1,490	-	n.m.
	515,857	583,075	(11.5%)	130,751	168,589	(22.4%)
Refinery and Processing	406,228	202,816	100.3%	100,464	79,590	26.2%
Inter-segment elimination	(306,561)	(159,393)	92.3%	(54,543)	(69,050)	(21.0%)
Total Sales	615,524	626,498	(1.8%)	176,672	179,129	(1.4%)

n.m. – not meaningful

EBITDA

	FY 2014	FY 2013	Change	4Q 2014	4Q 2013	Change
	US\$'000	US\$'000	%	US\$'000	US\$'000	%
Plantations and Palm Oil Mills	266,480	314,247	(15.2%)	77,737	89,538	(13.2%)
Refinery and Processing	32,688	26,802	22.0%	5,234	12,525	(58.2%)
Inter-segment elimination	580	(2,133)	n.m.	11,667	(5,718)	n.m.
Total EBITDA	299,748	338,916	(11.6%)	94,638	96,345	(1.8%)

n.m. – not meaningful

8. Review of Group Performance (continued)

REVIEW OF INCOME STATEMENT

Overview

The Group recorded a net profit of US\$173.4 million in FY2014, down 27.2% against FY2013 and a 20.5% decrease in profit from operations to US\$271.0 million. For 4Q2014, net profit decreased by 30.8% to US\$59.2 million while profit from operations declined by 25.3% to US\$88.9 million. Excluding the effect from the gains arising from changes in fair value of biological assets, the underlying net profit for the Group would have declined by 20.9% and 10.7% for FY2014 and 4Q2014 respectively. The declines in underlying net profit were mainly due to the lower average selling prices of crude palm oil and its refined products. This was partially offset by higher sales volumes from the Refinery and Processing segment, which was driven by the expansion of the Group's processing capacity.

Sales

Sales decreased by 1.8% to US\$615.5 million in FY2014 and 1.4% to US\$176.7 million in 4Q2014. These were mainly due to the lower average selling prices, partially offset by higher sales volumes from the Refinery and Processing segment.

Cost of Sales

Cost of sales comprises mainly harvesting costs, plantation maintenance costs, plantation general expenses and processing costs, as well as fresh fruit bunches and other palm oil products purchased from plasma farmers or third parties. The Group's cost of sales increased by 19.4% to US\$292.1 million in FY2014 and 5.3% to US\$74.7 million in 4Q2014, mainly driven by the higher production and sales volumes. For FY2014, the higher cost of sales was also contributed by the increase in purchases of palm oil products from third parties.

Gross Profit

Gross profit decreased by 15.3% to US\$323.4 million in FY2014 and 5.8% to US\$102.0 million in 4Q2014, mainly due to the lower average selling prices.

Gross profit margin came in at 52.5% in FY2014 as compared to 60.9% in the corresponding period last year, mainly due to the lower average selling prices as well as the increase in purchases of palm oil products from third parties. For 4Q2014, gross profit margin was at 57.7% as compared to 60.4% in 4Q2013, mainly due to the lower average selling prices.

Gains arising from changes in fair value of biological assets

The Group recognised gains arising from changes in fair value of biological assets amounting to US\$1.9 million in FY2014 and 4Q2014, as compared to US\$29.6 million in the corresponding period last year. The fair value of biological assets is determined based on the present value of their expected net cash flows. The lower fair value gains recognised in 2014 was mainly resulting from the effect of the higher discount rate used in the valuation as compared to the previous year.

Selling and Distribution costs

Selling and distribution expenses, comprising mainly export taxes and freight charges, totaled US\$24.3 million in FY2014 (FY2013: US\$37.2 million) and US\$6.1 million in 4Q2014 (4Q2013: US\$9.0 million). These decreases were mainly due to the reduction in export taxes paid, driven by the lower export tax rates applicable during 2014 in view of the lower prevailing palm oil prices.

General and Administrative expenses

General and administrative expenses declined to US\$28.3 million in FY2014 (FY2013: US\$31.6 million) and US\$8.5 million in 4Q2014 (4Q2013: US\$9.5 million), mainly due to lower accruals for employee related expenses. The decrease was also partly due to translation of the Group's Indonesian Rupiah ("IDR") denominated expenses into United States Dollar ("USD"), which resulted from the depreciation of IDR against USD.

8. Review of Group Performance (continued)

REVIEW OF INCOME STATEMENT (continued)

EBITDA

The Group's EBITDA came in at US\$299.7 million in FY2014, a decrease of 11.6% as compared to the corresponding period last year. In 4Q2014, EBITDA fell by 1.8% to US\$94.6 million as compared to 4Q2013. The declines in EBITDA were mainly due to the lower average selling prices of crude palm oil and its refined products, partially offset by the higher sales volumes generated by the Refinery and Processing segment.

Depreciation and Amortisation

Depreciation and amortisation increased by 11.0% to US\$30.7 million in FY2014 and 10.1% to US\$7.7 million in 4Q2014. The increases were largely due to the higher depreciation from the Group's new processing facilities and other property, plant and equipment.

(Losses)/Gains on Foreign Exchange

The Group recorded losses on foreign exchange of US\$0.1 million in FY2014 (FY2013: US\$6.4 million) and gains of US\$1.0 million in 4Q2014 (4Q2013: US\$1.1 million). The (losses)/gains on foreign exchange arose mainly from the impact of foreign currency movements on monetary assets and liabilities of the subsidiaries.

(Losses)/Gains on Derivative Financial Instruments

The Group recorded losses on derivative financial instruments of US\$2.8 million in FY2014 (FY2013: US\$2.6 million) and gains of US\$0.2 million in 4Q2014 (4Q2013: US\$2.9 million). These arose primarily from financial instruments entered into by the Group to hedge its exposure to foreign exchange and commodity price movements during the course of its business.

Net Financial Expenses

Net financial expenses comprise interest expenses after deducting interest income. Part of the interest expenses may be capitalised to immature plantations.

Net financial expenses totaled US\$15.0 million in FY2014, down 18.1% as compared to the corresponding period last year, mainly due to the Group's lower effective cost of borrowings through the issuances of the Islamic medium term notes. In 4Q2014, net financial expenses amounted to US\$4.2 million, an increase of 29.1% from 4Q2013, mainly due to the fourth issuance of Islamic medium term notes during 4Q2014.

The following table reflects the computation of net financial expenses:

	FY 2014	FY 2013	4Q 2014	4Q 2013
	US\$'000	US\$'000	US\$'000	US\$'000
Interest expenses and amortisation on loans and borrowings from financial institutions	338	6,258	134	(213)
Profit distribution and amortisation on Islamic medium term notes	19,786	15,842	5,666	4,758
	20,124	22,100	5,800	4,545
Less: Capitalised to biological assets	-	(243)	-	(180)
	20,124	21,857	5,800	4,365
Interest income	(5,104)	(3,525)	(1,551)	(1,074)
Net financial expenses	15,020	18,332	4,249	3,291

8. Review of Group Performance (continued)

REVIEW OF INCOME STATEMENT (continued)

Tax Expense and Net Profit

Tax expenses came in at US\$71.2 million in FY2014 (FY2013: US\$67.5 million) and US\$24.1 million in 4Q2014 (4Q2013: US\$31.9 million), with the Group's higher effective tax rates mainly due to increased income contributions from subsidiaries in higher tax jurisdictions, under provision of tax relating to prior years, as well as withholding tax expense on dividends from foreign subsidiaries.

As a result of the foregoing, profit attributable to owners of the Company decreased by 27.2% to US\$173.4 million in FY2014 and 30.8% to US\$59.2 million in 4Q2014.

REVIEW OF BALANCE SHEET

Total assets of the Group increased from US\$1,780.3 million as at 31 December 2013 to US\$1,997.9 million as at 31 December 2014. Non-current assets increased by US\$152.9 million to US\$1,522.9 million, mainly due to the Group's capital expenditure on biological assets and property, plant and equipment. The Group's current assets increased by US\$64.7 million to US\$474.9 million, mainly contributed by the higher cash and bank balances, partially offset by the lower inventories due to the drawdown in palm based products inventory volumes.

Total liabilities of the Group increased by 19.2% from US\$740.1 million as at 31 December 2013 to US\$882.1 million as at 31 December 2014, mainly due to the higher gross borrowings from the fourth issuance of Islamic medium term notes.

Gross borrowings increased by 19.1% to US\$583.1 million as at 31 December 2014 (31 December 2013: US\$489.7 million). Taking into consideration the increase in cash and bank balances during the period, net borrowings increased from US\$217.6 million as at 31 December 2013 to US\$232.2 million as at 31 December 2014. However, net gearing remains stable at a healthy level of 0.21x (31 December 2013: 0.21x).

REVIEW OF CASH FLOW STATEMENT

The Group generated net cash of US\$222.9 million from its operating activities in FY2014 as compared to US\$200.0 million in FY2013. In 4Q2014, net cash generated from operating activities amounted to US\$87.6 million as compared to US\$59.9 million in 4Q2013.

Net cash used in investing activities amounted to US\$214.5 million in FY2014 (FY2013: US\$235.5 million) and US\$67.7 million in 4Q2014 (4Q2013: US\$41.2 million), primarily relating to the Group's continued capital expenditure on oil palm plantations, palm oil mills and other property, plant and equipment. In addition, the higher cash used in investing activities in FY2013 also included US\$69.8 million for the acquisition of Lynhurst Investment Pte. Ltd. and its subsidiary.

Net cash generated from financing activities in FY2014 amounted to US\$43.0 million as compared to net cash used in financing activities of US\$109.4 million in FY2013. The cash used in financing activities in FY2013 included repayment of bank loans of US\$250.7 million, partially offset by US\$197.2 million of net proceeds received from the third issuance of Islamic medium term notes. In 4Q2014, the net cash generated from financing activities was US\$92.8 million (4Q2013: US\$3.8 million), which included US\$122.3 million of net proceeds received from the fourth issuance of Islamic medium term notes in 4Q2014.

Overall, the Group registered an increase in cash and cash equivalents of US\$51.4 million in FY2014, bringing the Group's cash and bank balances to US\$350.9 million as at 31 December 2014.

9. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results

Not applicable.

10. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months

Palm oil prices are likely to remain moderated, influenced by its relative pricing against crude oil and other competing edible oils such as soybean oil. However, recent developments in Indonesia's mandatory biodiesel policy should provide some support to prices by sustaining domestic demand for biodiesel.

Despite the volatility in commodity prices, the Group remains positive on the longer-term outlook of the palm oil industry.

Looking forward, the Group expects stronger production volumes in 2015 due to yield recovery and contribution from newly mature plantations. The young age profile of our plantations will continue to drive production volume growth in the longer term.

11. Dividends

(a) Current financial period reported on

Any dividend declared for the current financial period reported on?

Yes.

Name of Dividend	Interim dividend	Proposed final dividend
Dividend Type	Cash	Cash
Dividend Amount per Share	1.25 Singapore cents	2.30 Singapore cents
Tax Rate	Tax-exempt, one-tier	Tax-exempt, one-tier

(b) Corresponding period of the immediately preceding financial year

Any dividend declared for the corresponding period of the immediately preceding financial year?

Yes.

Name of Dividend	Interim dividend	Final dividend
Dividend Type	Cash	Cash
Dividend Amount per Share	1.25 Singapore cents	3.25 Singapore cents
Tax Rate	Tax-exempt, one-tier	Tax-exempt, one-tier

(c) Date payable

Payment of the proposed final dividend, if approved by the members at the Annual General Meeting to be held on 28 April 2015, will be made on 21 May 2015.

11. Dividends (continued)

(d) Books closure date

Notice is hereby given that the Register of Members and Register of Transfers of the Company will be closed on 8 May 2015 for the preparation of dividend warrants.

Duly completed registrable transfers received by the Company's Share Registrar, Boardroom Corporate & Advisory Services Pte. Ltd., 50 Raffles Place, #32-01, Singapore Land Tower, Singapore 048623, up to 5.00 p.m. on 7 May 2015 will be registered to determine shareholders' entitlements to the proposed final dividend. Members whose Securities Accounts with The Central Depository (Pte) Limited are credited with shares at 5.00 p.m. on 7 May 2015 will be entitled to the proposed final dividend.

12. If no dividend has been declared/recommended, a statement to that effect

Not applicable.

13. If the Group has obtained a general mandate from shareholders for IPTs, the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect

The Group has not obtained a general mandate from shareholders for Interested Person Transactions.

PART II - ADDITIONAL INFORMATION REQUIRED FOR FULL YEAR ANNOUNCEMENT

14. Segmented revenue and results for business or geographical segments (of the group) in the form presented in the issuer's most recently audited annual financial statements, with comparative information for the immediately preceding year

	Plantations and Palm Oil Mills	Refinery and Processing	Elimination	Total
FY 2014	US\$'000	US\$'000	US\$'000	US\$'000
Sales:				
External customers	209,296	406,228	-	615,524
Inter-segment	306,561	-	(306,561)	-
Total sales	515,857	406,228	(306,561)	615,524
Results:				
EBITDA	266,480	32,688	580	299,748
Depreciation and amortisation	(23,630)	(7,065)	-	(30,695)
Gains arising from changes in fair value of biological assets	1,940	-	-	1,940
Profit from operations	244,790	25,623	580	270,993
Losses on foreign exchange				(118)
Losses on derivative financial instruments				(2,777)
Net financial expenses				(15,020)
Other non-operating expenses				(1,133)
Profit before tax				251,945

14. **Segmented revenue and results for business or geographical segments (continued)**

	Plantations and Palm Oil Mills	Refinery and Processing	Elimination	Total
FY 2013	US\$'000	US\$'000	US\$'000	US\$'000
Sales:				
External customers	423,682	202,816	-	626,498
Inter-segment	159,393	-	(159,393)	-
Total sales	583,075	202,816	(159,393)	626,498
Results:				
EBITDA	314,247	26,802	(2,133)	338,916
Depreciation and amortisation	(22,586)	(5,060)	-	(27,646)
Gains arising from changes in fair value of biological assets	29,564	-	-	29,564
Profit from operations	321,225	21,742	(2,133)	340,834
Losses on foreign exchange				(6,368)
Losses on derivative financial instruments				(2,602)
Net financial expenses				(18,332)
Other non-operating income				32
Profit before tax				313,564

15. **In the review of performance, the factors leading to any material changes in contributions to turnover and earnings by the business or geographical segments**

Not applicable.

16. **A breakdown of sales**

	Group		
	FY 2014	FY 2013	Change
	US\$'000	US\$'000	%
Sales reported for first half year	290,089	294,320	(1.4%)
Profit after tax before deducting non-controlling interests reported for first half year	73,962	103,846	(28.8%)
Sales reported for second half year	325,435	332,178	(2.0%)
Profit after tax before deducting non-controlling interests reported for second half year	106,829	142,264	(24.9%)

17. A breakdown of the total annual dividend (in dollar value) for the issuer's latest full year and its previous full year

	FY 2014		FY 2013	
	S\$'000	US\$'000 equivalent	S\$'000	US\$'000 equivalent
Ordinary – Interim (paid)	19,801	15,850	19,801	15,534
Ordinary – Final (paid)	-	-	51,482	41,248
Ordinary – Final (proposed)	36,434	27,578*	-	-
Total	56,235	43,428	71,283	56,782

* based on SGD/USD exchange rate of 1.3211

18. Disclosure of person occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the issuer pursuant to Rule 704(13) in the format below. If there are no such persons, the issuer must make an appropriate negative statement

Name	Age	Family relationship with any director and/or substantial shareholder	Current position and duties, and the year the position was held	Details of changes in duties and position held, if any, during the year
Ciliandra Fangiono	38	Brother of Fang Zhixiang (Sigih Fangiono) (Director and Deputy Chief Executive Officer)	Director and Chief Executive Officer since 2007 - Responsible for overall management and strategic initiatives of the Group	No change
Fang Zhixiang (Sigih Fangiono)	37	Brother of Ciliandra Fangiono (Director and Chief Executive Officer)	Deputy Chief Executive Officer since 2007 - Responsible for the Group's daily operations, including new plantations development	Director since 2014

BY ORDER OF THE BOARD

Ciliandra Fangiono

Director and Chief Executive Officer

26 February 2015